Anebulo Pharmaceuticals Income Statement

Financials in millions USD. Fiscal year is July - June.

Millions USD. Fiscal year is Jul - Jun.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	2020
Period Ending	Dec '25 Dec 31, 2025	Jun '25 Jun 30, 2025	Jun '24 Jun 30, 2024	Jun '23 Jun 30, 2023	Jun '22 Jun 30, 2022	Jun '21 Jun 30, 2021	2020
Selling, General & Admin	5.36	4.92	4.76	6.18	3.87	1.34	Upgrade
Research & Development	3.74	4.3	3.55	5.6	2.96	2.27	Upgrade
Operating Expenses	9.1	9.22	8.31	11.78	6.83	3.61	Upgrade
Operating Income	-9.1	-9.22	-8.31	-11.78	-6.83	-3.61	Upgrade
Interest Expense	-0.3	-0.38	-0.15	-	-	-0.01	Upgrade
Interest & Investment Income	0.42	0.26	0.25	0.09	0.01	0	Upgrade
Other Non Operating Income (Expenses)	1	0.86	0.01	-0.04	-0	-26.63	Upgrade
Pretax Income	-7.98	-8.48	-8.2	-11.73	-6.83	-30.25	Upgrade
Net Income	-7.98	-8.48	-8.2	-11.73	-6.83	-30.25	Upgrade
Preferred Dividends & Other Adjustments	-	-	-	-	-	8.21	Upgrade
Net Income to Common	-7.98	-8.48	-8.2	-11.73	-6.83	-38.46	Upgrade
Shares Outstanding (Basic)	41	34	26	25	23	14	Upgrade
Shares Outstanding (Diluted)	41	34	26	25	23	14	Upgrade
Shares Change (YoY)	55.97%	30.97%	2.98%	7.41%	71.49%	13.44%	Upgrade
EPS (Basic)	-0.19	-0.25	-0.32	-0.47	-0.29	-2.83	Upgrade
EPS (Diluted)	-0.19	-0.25	-0.32	-0.47	-0.29	-2.83	Upgrade
EBIT	-9.1	-9.22	-8.31	-11.78	-6.83	-3.61	Upgrade

Source: S&P Capital IQ. Standard template. Financial Sources.